Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone - Seite 3

Roluperidone Phase 3: ITT and mITT NSFS & PSP total score change from baseline scores and p-values
Timepoint	Intent-to-Treat			Modified Intent-to-Treat (Excluding patients from 1 site)
	Placebo (N=172)	64 mg Roluperidone (N=171)	p-value	Placebo (N=167)	64 mg Roluperidone (N=162)	p-value
Primary Endpoint: Marder Negative Symptoms Factor Score
Week 2	-1.6 (0.22)	-1.9 (0.22)	NS	-1.6 (0.22)	-1.9 (0.22)	0.311
Week 4	-2.0 (0.26)	-2.9 (0.26)	0.007	-2.0 (0.26)	-3.0 (0.27)	0.005
Week 8	-2.9 (0.30)	-3.8 (0.32)	0.027	-2.9 (0.31)	-3.9 (0.32)	0.021
Week 12	-3.5 (0.34)	-4.3 (0.38)	0.064	-3.5 (0.35)	-4.5 (0.35)	0.044
Key Secondary Endpoint: Personal and Social Performance Total Score
Week 4	1.3 (0.56)	3.2 (0.56)	0.005	1.2 (0.58)	3.3 (0.59)	0.004
Week 8	2.8 (0.66)	4.8 (0.66)	0.019	2.8 (0.68)	4.9 (0.68)	0.014
Week 12	3.9 (0.73)	6.1 (0.73)	0.021	3.8 (0.75)	6.2 (0.77)	0.017

About Minerva Neurosciences:

Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.